Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

1996 • 3,649 citations

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

2006 • 3,441 citations

Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]

1995 • 2,026 citations

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

2006 • 1,296 citations

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

2003 • 1,253 citations

IFNα activates dormant haematopoietic stem cells in vivo

2009 • 1,230 citations

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

2006 • 1,199 citations

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

2002 • 1,194 citations

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1996 • 1,080 citations

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

2000 • 679 citations

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

2006 • 647 citations

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

2003 • 554 citations

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

2006 • 539 citations

Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells

1996 • 341 citations

Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders

2001 • 329 citations

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

2007 • 307 citations

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

2004 • 286 citations

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

1999 • 285 citations

Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis

2003 • 222 citations

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells

2003 • 219 citations

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

2000 • 197 citations

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

2004 • 168 citations

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

2002 • 140 citations

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

2004 • 135 citations

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia

2007 • 135 citations

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

2009 • 121 citations

Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa

2002 • 116 citations

Ex Vivo Characterization of Multiepitopic Tumor-Specific CD8 T Cells in Patients with Chronic Myeloid Leukemia: Implications for Vaccine Development and Adoptive Cellular Immunotherapy

2005 • 110 citations

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.

2005 • 105 citations

Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa

2002 • 68 citations

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

2005 • 55 citations

BCR-ABL Activity Is Critical for the Immunogenicity of Chronic Myelogenous Leukemia Cells

2007 • 51 citations

Economic evaluations of leukemia: A review of the literature

2007 • 38 citations

High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial.

2009 • 35 citations

Interferon a and T-cell responses in chronic myeloid leukemia

2004 • 35 citations

Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.

2009 • 33 citations

Can we afford to let sleeping dogs lie?

2005 • 21 citations

Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia

2004 • 19 citations

The immunogenicity of Bcr-Abl–expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl–regulated antigens

2007 • 18 citations